NCT00768963

Ranibizumab for the Inhibition of Neovascularization in Pterygia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.

Detailed description

As a secondary objective, this study also aims to establish the tissue concentration of ranibizumab when delivered via subconjunctival injection in patients undergoing pterygium excision and to determine the effects of ranibizumab on conjunctival healing, corneal epithelial healing, and wound dehiscence.

Conditions

• Pterygium

Interventions

Type	Name	Description
DRUG	ranibizumab	0.5 mg subconjunctival ranibizumab 3 days prior to surgery
DRUG	ranibizumab	0.5 mg subconjunctival ranibizumab at the time of surgery

Timeline

• Start date: 2008-10-01
• Primary completion: 2011-11-01
• Completion: 2012-01-01
• First posted: 2008-10-08
• Last updated: 2017-07-11

Locations

1 site across 1 country: United States